Elicit: Clinical Outcomes of Palbociclib and Fulvestrant in PALOMA-3
Clinical Outcomes of Palbociclib and Fulvestrant in PALOMA-3
Palbociclib plus fulvestrant clinical outcomes PALOMA-3
In the PALOMA-3 trial, palbociclib plus fulvestrant improved progression-free survival by approximately 5 months, overall survival by 6.9 months, and doubled time to chemotherapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer progressing on prior endocrine therapy, with a manageable safety profile dominated by reversible hematologic toxicity.
Abstract
The PALOMA-3 trial demonstrated substantial clinical benefit for palbociclib plus fulvestrant in hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy. Across multiple analyses with follow-up extending to 73.3 months, palbociclib plus fulvestrant consistently improved median progression-free survival by approximately 5 months compared to placebo plus fulvestrant (9.2-11.2 months vs 3.8-4.6 months, HR 0.42-0.50, p<0.001). The most recent analysis showed median overall survival of 34.8 months versus 28.0 months (HR 0.81, 95% CI 0.65-0.99), with greater benefit observed in patients with endocrine-sensitive disease who had not received prior chemotherapy for metastatic disease (39.3 vs 29.7 months, HR 0.72). Palbociclib plus fulvestrant doubled the median time to receipt of chemotherapy (17.6 vs 8.8 months, HR 0.58, p<0.001).
The safety profile was characterized by predictable hematologic toxicity, with grade 3-4 neutropenia occurring in 52-65% of patients but febrile neutropenia remaining low at 0.6-4.1%. Treatment discontinuation rates due to adverse events were minimal (2.0-2.6%), and dose intensity was maintained at 89.7% despite frequent dose modifications. Clinical benefit was consistent across menopausal status, geographic populations including Asian patients (HR 0.485), and molecular subtypes, with palbociclib providing benefit regardless of ESR1, PIK3CA, or TP53 mutation status. Quality of life was maintained with no significant deterioration from baseline.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Screening Criteria
- Patient Population - Disease Type: Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer progressing on prior endocrine therapy.
- Intervention Type: Evaluation of palbociclib in combination with fulvestrant.
- Clinical Outcomes Reported: Reported clinical outcomes including efficacy and safety.
- Study Design: Randomized controlled trial, systematic review, meta-analysis, or post-hoc analysis of PALOMA-3.
- Patient Age: Adult patients (≥18 years).
- Combination Therapy Focus: Focus on palbociclib plus fulvestrant.
- Human Clinical Evidence: Human clinical studies only.
- Full Publication Available: Full-text publications only.
Data extraction
Efficacy Outcomes
- Primary Endpoint Results (Progression-Free Survival): Median PFS improved significantly, HR 0.42-0.50, p<0.001.
Safety Profile
- Overall adverse event rates were higher in the palbociclib group compared to placebo, with significant grade 3-4 events.
Patient Characteristics
- Sample Size: 521 women randomized (347 palbociclib, 174 placebo).
- Median Age: 57 years. 79% post-menopausal.
Overall Survival Analysis
Overall survival (OS) analyses evolved with longer follow-up. The initial prespecified OS analysis showed median OS of 34.9 months for palbociclib plus fulvestrant versus 28.0 months for placebo plus fulvestrant (HR 0.81).
Time to Subsequent Therapy
Palbociclib plus fulvestrant significantly delayed chemotherapy initiation. Median time to chemotherapy was 17.6 months versus 8.8 months for placebo.
Safety and Tolerability
Adverse events included neutropenia and other common hematologic toxicities. Dose modifications occurred frequently, but overall safety remained managed well.
Conclusions
The PALOMA-3 trial demonstrated consistent clinical benefits of palbociclib plus fulvestrant for patients with HR-positive, HER2-negative metastatic breast cancer, with substantial improvements in progression-free survival and overall survival among certain patient subgroups.
References
- Key Publications